+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 44 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating treatments for germinal center B-cell-like diffuse large B-cell lymphoma GCB DLBCL, a fast-growing blood cancer affecting immature B-cells. The study aims to determine if more people respond to zilovertamab vedotin MK-2140 combined with R-CHP compared to polatuzumab vedotin combined with R-CHP. This is a phase 2 randomized study focused on participants who have not been treated before and have the GCB subtype of DLBCL. Participants will be randomly assigned to receive either zilovertamab vedotin plus cyclophosphamide, doxorubicin, rituximab or its biosimilar R-CHP, or polatuzumab vedotin plus R-CHP. These drugs are given by intravenous infusion on Day 1 of each 3-week cycle for up to 6 cycles, about 4 months. Additionally, participants take prednisone or prednisolone tablets daily on Days 1 to 5 of each cycle. Those with high-risk DLBCL may receive 2 extra cycles of rituximab or its biosimilar. Throughout the study, participants undergo assessments including PET scans to monitor cancer response, and various health evaluations. Researchers measure complete response rate at the end of treatment, progression-free survival, overall survival, event-free survival, and quality of life using standardized tools. Safety is monitored by tracking adverse events and treatment tolerability. The study lasts up to several years with follow-up for long-term outcomes.

Age: 18Years +All GendersPhase 2
148 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
304 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a new approach to prevent cardiovascular events in people at increased risk due to age and conditions like diabetes, prediabetes, or metabolic syndrome but who do not have symptoms of cardiovascular disease. The study compares a personalized care strategy based on the Cleerly Coronary Artery Disease CAD Staging System with the usual risk factor-based care. This approach aims to better identify and treat individuals with underlying atherosclerosis to reduce cardiovascular events. Participants are randomly assigned to one of two groups. The risk factor-based care group is managed by their usual healthcare providers, with oversight from a centralized cardiology team that monitors treatments and lab results without seeing coronary imaging results. The Cleerly stage-based care group receives personalized management from a remote cardiologist-led team using the Cleerly CAD Staging System, which includes coronary artery imaging, algorithm-driven medication adjustments, and education. Care is intensified if plaque worsens at 24 months. During the study, participants undergo assessments including coronary computed tomography angiography CCTA and lab tests. Researchers monitor cardiovascular events over an average of 3.5 years to compare the two care strategies. Medication use, lab values, and clinical outcomes related to cardiovascular and kidney health are tracked. The study includes electronic communication tools to support personalized care and aims to improve prevention through more precise disease staging and management.

Age: 55Years +All GendersPhase Not Applicable
125 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
R

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and treatment experience of participants prescribed BRIUMVI4 ublituximab-xiiy for relapsing multiple sclerosis RMS in a real-world setting. The study aims to gather insights over time on how this treatment works outside of controlled clinical trials. Participants will receive BRIUMVI4 ublituximab-xiiy through intravenous infusion as part of their routine care for RMS. This observational study follows these participants longitudinally to monitor their health and treatment experience without assigning any new interventions. During the study, participants will be monitored for relapses, adverse events, and infusion-related reactions up to 96 weeks. Researchers will collect data from medical records and routine visits to assess annualized relapse rates and safety outcomes, supporting a comprehensive understanding of treatment effects in everyday clinical practice. The study duration extends until 2032, allowing for long-term follow-up.

Age: 18Years +All Genders
113 locations
G

Actively Recruiting

Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.

Age: 18Years +All GendersPhase 3
415 locations
P

Actively Recruiting

Researchers are evaluating whether intismeran autogene, given with pembrolizumab and chemotherapy, can improve outcomes for people with metastatic treatment-naive squamous non-small cell lung cancer NSCLC. This study compares the combination of intismeran autogene with pembrolizumab and chemotherapy against a placebo with pembrolizumab and chemotherapy to see if it helps patients live longer without the cancer growing or spreading. The trial is a randomized, double-blind, placebo-controlled Phase 2 study sponsored by Merck Sharp & Dohme LLC. Participants receive treatments in two phases induction and maintenance. During the induction phase, pembrolizumab is given by intravenous infusion every six weeks combined with a platinum-based chemotherapy regimen and either paclitaxel or nab-paclitaxel. Intismeran autogene or placebo injections are administered intramuscularly on specific days during the induction phase. In the maintenance phase, pembrolizumab continues every six weeks, and intismeran autogene or placebo injections are given every three weeks for up to seven doses. Participants will be closely monitored throughout the study with regular assessments including scans, laboratory tests, and evaluations of their cancers response and overall health. The main outcomes measured are progression-free survival and overall survival over approximately 32 to 42 months. Secondary outcomes include response rates, duration of response, and the occurrence of side effects. The study aims to collect comprehensive data to understand the effects and safety of the study treatment combination compared to placebo.

Age: 18Years +All GendersPhase 2
55 locations
R

Actively Recruiting

Researchers are studying Raludotatug Deruxtecan R-DXd, an antibody-drug conjugate that targets CDH6 protein, in people with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer. This trial includes a Phase 2 dose-optimization part to find the best dose based on safety and effectiveness, followed by a Phase 3 part comparing R-DXd to chemotherapy chosen by the investigator. Participants will receive R-DXd through an intravenous infusion every three weeks at varying doses during Phase 2. In Phase 3, participants will be randomly assigned to receive either R-DXd at the recommended dose or one of the chemotherapy options paclitaxel, pegylated liposomal doxorubicin PLD, or topotecan, also given intravenously every three weeks. During the study, participants will undergo scans and biopsies to evaluate tumor response and drug effects. Researchers will monitor safety, side effects, and various measures such as progression-free survival and overall survival for up to 40 months. Participants will have regular visits for treatment, assessments, and laboratory tests to track their health and response to the study treatments.

Age: 18Years +All GendersPhase 2Phase 3
167 locations
E

Actively Recruiting

Researchers are studying the effects of prasinezumab, given as an intravenous infusion, in people aged 50 to 85 with early-stage Parkinsons disease who are already receiving stable levodopa treatment. The study aims to compare prasinezumab to a placebo to evaluate its safety, how the body processes the drug, and its impact on motor symptoms related to Parkinsons disease. Participants will be randomly assigned to receive either prasinezumab or a placebo through IV infusions during the double-blind treatment phase. After this phase, eligible participants can join an open-label extension where they receive prasinezumab. The study follows participants for at least 104 weeks, with infusions and assessments scheduled throughout this period. During the study, participants will have regular visits for motor function assessments using the Movement Disorder Society Unified Parkinsons Disease Rating Scale MDS-UPDRS and other measures. Researchers will monitor adverse events, infusion reactions, and the presence of antibodies against prasinezumab. Blood samples will be taken at multiple time points to measure drug levels and immune responses. The total study duration extends through 2031, including safety follow-up after the last dose.

Age: 50Years - 85YearsAll GendersPhase 3
192 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of sonrotoclax combined with zanubrutinib compared to zanubrutinib with placebo in adults who have relapsed or refractory mantle cell lymphoma MCL, a rare and aggressive blood cancer. The study focuses on whether the combination of sonrotoclax and zanubrutinib can better control the disease and improve patient outcomes. Participants will be randomly assigned to one of two groups one receiving sonrotoclax plus zanubrutinib, and the other receiving zanubrutinib plus a placebo. All treatments are taken orally. The placebo is a pill without active medicine. The study design is double-blind, so neither participants nor doctors know which treatment is given during the trial unless medically necessary. The study will last up to approximately 7 years. During this time, participants will visit clinics regularly for treatment, health assessments, blood tests, and tumor imaging. Researchers will measure how long participants live without disease worsening, overall survival, response rates, quality of life, and safety through side effect monitoring. These evaluations will help understand the treatments impact on the disease and patient wellbeing.

Age: 18Years +All GendersPhase 3
145 locations

1-10 of 44

1